Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia
Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia
复制标题
DOI：
10.1210/jc.2015-3246
复制
发表时间：
2016-02-01
影响因子：
5.8
通讯作者：
Boyko, Edward J.
中科院分区：
文献类型：
--
作者：
Hwang, You-Cheol;Fujimoto, Wilfred Y.;Boyko, Edward J.
背景：动脉粥样硬化性血脂异常常见于内脏脂肪组织（VAT）较多的人群。然而，目前还不确定VAT是否与动脉粥样硬化性血脂异常的未来发展独立相关。目的：本研究的目的是确定VAT和皮下脂肪组织（SAT）的基线和变化是否与动脉粥样硬化性血脂异常的未来发展相关，而与基线血脂水平和标准人体测量指标无关。以社区为基础的前瞻性队列研究，随访5年。参与者：共452名日裔美国人（240名男性，212名女性），年龄34-75岁，在基线和5年后的following.Main结果测量：腹部脂肪面积进行了评估，通过计算机断层扫描。动脉粥样硬化性血脂异常是指一种或多种高密度脂蛋白（HDL）胆固醇、甘油三酯或非HDL胆固醇水平的异常。基线VAT和5年内VAT的变化与5年后对数转换的HDL胆固醇、对数转换的甘油三酯和非HDL胆固醇独立相关（标准化β分别为基准增值税的-0.126，0.277和0.066，增值税变化的β分别为-0.095，0.223和0.090）。然而，基线和SAT的变化与任何未来致动脉粥样硬化的脂质水平无关。在多变量logistic回归分析中，增值税的增量变化（比值比[95%置信区间]，1.73 [1.20-2.48]; P = .003），甘油三酯（4.01 [1.72-9.33]; P < .001），HDL胆固醇（0.32 [0.18-0.58]; P < .001），非HDL胆固醇（7.58 [4.43-12.95]; P < .001）与致动脉粥样硬化性血脂异常的未来发展显著相关，与年龄、性别、舒张压、稳态模型评估胰岛素抵抗、体重指数（BMI）、结论：基线和VAT的变化是未来动脉粥样硬化性血脂异常发展的独立预测因子。然而，BMI、腰围和SAT与致动脉粥样硬化性血脂异常的未来发展无关。
Context: Atherogenic dyslipidemia is frequently observed in persons with a greater amount of visceral adipose tissue (VAT). However, it is still uncertain whether VAT is independently associated with the future development of atherogenic dyslipidemia.Objectives: The aim of this study was to determine whether baseline and changes in VAT and subcutaneous adipose tissue (SAT) are associated with future development of atherogenic dyslipidemia independent of baseline lipid levels and standard anthropometric indices.Design and Setting: Community-based prospective cohort study with 5 years of follow-up.Participants: A total of 452 Japanese Americans (240 men, 212 women), aged 34-75 years were assessed at baseline and after 5 years of follow-up.Main Outcome Measures: Abdominal fat areas were measured by computed tomography. Atherogenic dyslipidemia was defined as one or more abnormalities in high-density lipoprotein (HDL) cholesterol, triglycerides, or non-HDL cholesterol levels.Results: Baseline VAT and change in VAT over 5 years were independently associated with log-transformed HDL cholesterol, log-transformed triglyceride, and non-HDL cholesterol after 5 years (standardized beta = -0.126, 0.277, and 0.066 for baseline VAT, respectively, and -0.095, 0.223, and 0.090 for change in VAT, respectively). However, baseline and change in SAT were not associated with any future atherogenic lipid level. In multivariate logistic regression analysis, incremental change in VAT (odds ratio [95% confidence interval], 1.73 [1.20-2.48]; P = .003), triglycerides (4.01 [1.72-9.33]; P < .001), HDL cholesterol (0.32 [0.18-0.58]; P < .001), and non-HDL cholesterol (7.58 [4.43-12.95]; P < .001) were significantly associated with the future development of atherogenic dyslipidemia independent of age, sex, diastolic blood pressure, homeostasis model assessment insulin resistance, body mass index (BMI), change in BMI, SAT, and baseline atherogenic lipid levels.Conclusion: Baseline and change in VAT were independent predictors for future development of atherogenic dyslipidemia. However, BMI, waist circumference, and SAT were not associated with future development of atherogenic dyslipidemia.